← Leaderboards
Rebecca J Beyth
Baylor College Of Medicine
$2,749,412
Attributed
$2,749,412
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $539.1K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$2,749,412 · 2
By mechanism
R01$2,534,467 · 1
K08$214,945 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Powel H Brown$10,794,797
- Xander H.t. Wehrens$19,095,667
- William Thomas Shearer$34,592,326
- Na Li$10,401,980
- C Kent Osborne$24,386,086
Others in their field
Top investigators on “Atrial Fibrillation”
- Paul M. Ridker · Brigham And Women'S Hospital$55,416,022
- Dan M Roden · Vanderbilt University Medical Center$46,715,542
- Jane Wilkinson · Broad Institute, Inc.$38,181,500
- Stacey Gabriel · Massachusetts Institute Of Technology$34,637,180
- Mark J Daly · Broad Institute, Inc.$34,637,180
- Bruce M Psaty · University Of Washington$27,684,589
Research focus
Atrial FibrillationHuman SubjectHuman Therapy EvaluationClinical ResearchWarfarinAnticoagulantsClinical TrialsChemopreventionStrokeAspirinPatient Care ManagementPatient Oriented ResearchComorbidityAttitudeBeliefBlood CoagulationAgingDrug Adverse EffectDrug Screening /EvaluationHuman Old Age (65+)Questionnaires
Grant awards (7)
Improving Anti-Thrombotic Use in Stroke Prevention$539,054
R01 · FY2006 · HL · contact PI
Improving Anti-Thrombotic Use in Stroke Prevention$515,571
R01 · FY2005 · HL
Improving Anti-Thrombotic Use in Stroke Prevention$495,612
R01 · FY2004 · HL
Improving Anti-Thrombotic Use in Stroke Prevention$474,042
R01 · FY2003 · HL
Improving Anti-Thrombotic Use in Stroke Prevention$510,188
R01 · FY2002 · HL
IMPROVING THE USE OF ANTICOAGULANT THERAPY IN THE AGED$112,535
K08 · FY2001 · AG
IMPROVING THE USE OF ANTICOAGULANT THERAPY IN THE AGED$102,410
K08 · FY2000 · AG